All In Biotech

Drug Trial Radar · NCT00388726

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Last checked: Nov 19, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 762 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

762

Actual

Start

Nov 2006

Primary completion

May 2009

Study completion Jun 2013

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Eisai Limited
First posted
Oct 17, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • E7389Drug

    1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.

  • Physician's ChoiceDrug

    Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From date of randomization until death from any cause

Locations

137 sites in 17 countries. Site status is shown where the registry gives one.

  • US Oncology St. Vincent's Hospital - Bruno Cancer Center

    Birmingham, Alabama

  • Bellflower Satellite

    Bellflower, California

  • Research Center

    Gilroy, California

  • US Oncology

    Denver, Colorado

  • Florida Cancer Research Institute

    Davie, Florida

  • Innovative Medical Research of South Florida, Inc.

    Miami, Florida

  • Peachtree Hematology/Oncology Consultants, PC

    Atlanta, Georgia

  • US Oncology

    Niles, Illinois

  • US Oncology

    Indianapolis, Indiana

  • University of Iowa Hospital and Clinic

    Iowa City, Iowa

  • Hematology Oncology Clinic

    Baton Rouge, Louisiana

  • Oncology Care Associates, P.L.L.C.

    Saint Joseph, Michigan

  • US Oncology

    Columbia, Missouri

  • Montana Cancer Specialists

    Missoula, Montana

  • US Oncology

    Las Vegas, Nevada

  • US Oncology

    Albany, New York

  • North Shore Hematology/Oncology Associates

    East Setauket, New York

  • Weill Cornell Breast Cancer Center

    New York, New York

  • Carolina Hematology Oncology Associates

    Charlotte, North Carolina

  • US Oncology

    Raleigh, North Carolina

  • US Oncology

    Eugene, Oregon

  • St. Vincent Medical Center

    Portland, Oregon

  • US Oncology

    Bedford, Texas

  • US Oncology

    Dallas, Texas

  • US Oncology

    Houston, Texas

  • US Oncology

    McAllen, Texas

  • US Oncology

    Midland, Texas

  • US Oncology

    Tyler, Texas

  • US Oncology

    Spokane, Washington

  • Northwest Medical Specialists

    Tacoma, Washington

  • US Oncology

    Vancouver, Washington

  • US Oncology

    Yakima, Washington

  • Hosptial Interzonal General de Mar del Plata

    Buenos Aires, Argentina

  • Clinica Universitaria Privada Reina Fabiola

    Córdoba, Argentina

  • Sanatorio Frances

    Córdoba, Argentina

  • Instituto de Oncologia y Especialidades Medicas

    Rosario Santa Fe, Argentina

  • Clinica Especializada ISIS

    Santa Fe, Argentina

  • Instituto Oncologico "Las Heras"

    Bahía Blanca, Buenos Aires, Argentina

  • Hospital Britanico

    C.a.b.a, Buenos Aires, Argentina

  • Instituto FIDES especialidades Medicas

    La Plata, Buenos Aires, Argentina

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.